The EPICOLON consortium was initiated in 1999 by the Gastrointestinal Oncology Group of the Spanish Gastroenterology Association. It recruited consecutive, unselected, population-based colorectal cancer (CRC) cases and control subjects matched by age and gender without personal or familial history of cancer all over Spain with the main goal of gaining knowledge in Lynch syndrome and familial CRC. This epidemiological, prospective and multicentre study collected extensive clinical data and biological samples from $2000 CRC cases and 2000 controls in Phases 1 and 2 involving 25 and 14 participating hospitals, respectively. Genetic susceptibility projects in EPICOLON have included candidate-gene approaches evaluating single-nucleotide polymorphisms/ genes from the historical category (linked to CRC risk by previous studies), from human syntenic CRC susceptibility regions identified in mouse, from the CRC carcinogenesisrelated pathways Wnt and BMP, from regions 9q22 and 3q22 with positive linkage in CRC families, and from the mucin gene family. This consortium has also participated actively in the identification 5 of the 16 common, lowpenetrance CRC genetic variants identified so far by genome-wide association studies. Finishing their own pangenomic study and performing whole-exome sequencing in selected CRC samples are among EPICOLON future research prospects.
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Preface
Colorectal cancer (CRC) continues to be a major public health problem, although it is a preventable and potentially curable neoplasm. CRC is the second most common cancer in Western countries and it also represents the second leading cause of cancer-related death among men and women. In the USA, there were 102 900 estimated new CRC cases diagnosed during 2010 and 51 370 deaths related to this cancer in the same year (26 580 males and 24 790 women) (1) . Risk of developing this neoplasm in the general population is around 5-6% at the age of 70, and it rises exponentially with age.
Genetic factors involved in CRC susceptibility
Familial aggregation is defined as occurrence of CRC in more members of a family than can be readily accounted for by chance (2) . Familial clustering may be caused by sharing either genetic predisposition or environmental factors. Regarding CRC, these environmental effects may be particularly relevant because families share dietary customs and recreational habits. Obesity, sedentary life, cigarette smoking or a diet rich in fat and red meat are among the high-risk environmental factors most commonly considered for CRC and monitoring them is important in terms of prevention strategies (3) . On the other hand, epidemiological studies have also assessed the contribution of shared environment in cancers using twin studies to measure if concordance for cancer is higher among monozygotic twins who have a common genetic background than among dizygotic twins who, on average, share half of their segregating genes. A survey performed in Scandinavian population concluded that inherited genetic factors seem to make a minor contribution to susceptibility in most types of cancers, indicating that environment has the primary responsibility. However, this study also detected a relatively higher effect of heritability in prostate and CRC (4) . A more recent study in a similar population explored the extension of the risk for CRC due to heritable genetic or environmental factors. It included all first-degree relatives (parents, siblings and children) and spouses, concluding that genetic effects are likely to be more important for CRC than environment (5) .
Familial adenomatous polyposis and Lynch syndrome are the more frequent hereditary CRC syndromes and they are caused by germ line mutations in APC, MUTYH and mismatch repair (MMR) genes MLH1, MSH2, MSH6 and PMS2, respectively (2). These hereditary Mendelian syndromes show earlier onset and stronger familial aggregation than familial non-syndromic CRC. However, they only correspond to a minority of the total CRC burden (5%). The genetic components involved in these less frequent hereditary forms were successfully identified in the past two decades and they correspond to rare highly penetrant alleles that predispose to CRC. Excluding these hereditary syndromes, most CRC cases do not have a positive family history and they are considered sporadic, although there is some familial aggregation in an important percentage corresponding to the familial CRC category ($30% of total CRC cases) (6) .
Genetic variants predisposing to familial CRC are mainly not identified, and, therefore, most heritability factors involved in CRC still remain unrevealed. Among CRC cases with an unknown germ line genetic basis, CRC cases with a strong familial aggregation without MMR involvement, also known as familial CRC type X (7), are particularly interesting. In these CRC families, strict clinical Amsterdam I criteria are met: (i) at least three CRC cases with histological confirmation (one firstdegree relative of the other three), excluding familial adenomatous polyposis; (ii) at least two successive generations affected and (iii) one of the relatives is affected with CRC before age 50.
Recently, new common low-penetrance genetic variants for CRC have been identified by case-control genome-wide association studies (GWAS) permitting to point out so far 14 loci for CRC genetic susceptibility in chromosomal regions 8q23. 3 (8, 9) . Additionally, genetic linkage efforts in families with several members affected with familial CRC have allowed also pinpointing other candidate chromosomal regions for CRC genetic susceptibility. Among them, the more solid runners-up are 9q22 (10-13) and 3q21-q24 (14) (15) (16) (17) . Moreover, there is also very preliminary evidence of the implication of new genes in familial CRC. Examples could be the GALNT12 gene in region 9q22, highly expressed in the digestive system and involved in glycosilation of proteins such as mucins (18) or the BMP4 and PTPRJ genes (19, 20 Demographic, clinical and tumour-related characteristics, as well as a detailed family history, were obtained from CRC cases using a pre-established questionnaire. Personal parameters at baseline included place and date of birth, gender, personal history of neoplasia (LS-related tumours and colorectal adenomas), age at CRC diagnosis and presence of synchronous colorectal neoplasms. Tumour-related parameters included location, histology, TNM stage and degree of differentiation. Synchronous lesions were assessed by colonoscopy before or immediately after surgery, as well as through systematic review of the resected specimen. Pedigrees were traced backward and laterally as far as possible, and at least out to second-degree relatives, with regard to cancer history. Age at cancer diagnosis, type and location were registered for each affected family member. Demographic, clinical and tumour-related characteristics of CRC patients included are shown in Table I . Exclusion criteria for CRC cases in EPICOLON were familial adenomatous polyposis and personal history of inflammatory bowel disease. This study was approved by the institutional ethics committee of each participating hospital and written informed consent was obtained from all patients.
Efforts made by all EPICOLON participating centres permitted to collect extensive clinical data and biological samples from $2000 CRC cases and 2000 controls and to perform during the past decade several studies ascertaining epidemiological, diagnostic and molecular aspects on Lynch syndrome and familial CRC. A first study established a 2.5% frequency for clinical diagnosis of Lynch syndrome in Spain according to the Amsterdam II criteria (21) . Subsequent studies focused on the clinical characterisation of this cohort concerning synchronous (25, 33) , MMR mutation prediction tools (34, 35) or tumour response to fluorouracil (5-FU) adjuvant chemotherapy according to the MMR status (36, 37) .
CRC genetic predisposition projects within EPICOLON
Besides the above-mentioned studies, there have also been several efforts in EPICOLON to identify or evaluate new lowpenetrance genetic susceptibility variants for CRC. For this purpose, germ line DNA samples from CRC cases and age-and gender-matched controls without personal or family history of cancer were available from this cohort to perform genetic association case-control studies. Five hundred and fifteen CRC samples and 515 controls were collected in EPICOLON Phase 1, corresponding to a selection of samples with sufficient DNA quality to be genotyped with high-throughput genotyping techniques. The number of germ line DNA samples available from CRC cases in Phase 1 was actually higher ($1100) and they were all included in some studies when it was permitted by the used genotyping approach (i.e. real-time polymerase chain reaction assays with hydrolysis probes). Regarding EPICOLON Phase 2, high-quality germ line DNA was available from .900 CRC cases and equal number of matched controls. Since 2005, several genetic association candidate-gene approaches have been pursued within EPICOLON aiming to identify genetic susceptibility variants for CRC. Firstly, singlenucleotide polymorphisms (SNPs)/genes were selected to be studied from the historical category (linked to CRC risk by previous studies), from human syntenic CRC susceptibility regions identified in mouse, from the CRC carcinogenesis-related pathways Wnt and BMP, from regions 9q22 and 3q22 with positive linkage in CRC families and from the mucin gene family. A first study evaluated the genetic variation in the ARLTS1 gene (38) in EPICOLON Phase 1, a tumour suppressor gene of the ADP-ribosylation factor family with proapoptotic characteristics identified in chromosome 13q14 and potentially involved in susceptibility to familial cancer. Variant p.C148R (c.442T.C; rs3803185) showed for the first time in CRC statistically significant differences between cases and controls [odds ratio (OR) 5 1.45, 95% confidence interval (95% CI) 5 1.13-1.86, P 5 0.003], sporadic cases and controls (OR 5 1.59, 95% CI 5 1.13-2.23, P 5 0.007) and familial cases and controls (OR 5 1.55, 95% CI 5 1.10-2.19, P 5 0.01) in agreement with a hypothetical moderate increase of the cancer risk linked to the C148R ARLTS1 variant, both in sporadic and familial CRC cases.
Next candidate-gene approach in EPICOLON analysed the human-mouse syntenic regions defined by 15 Susceptibility to CRC (Scc) loci, searching for relevant genes that could be functionally related to carcinogenetic processes. Selection of these genes was performed on the basis of enriched expression in primary affected tissues in humans. Once the 21 candidate genes were chosen, 147 SNPs within them were genotyped in 515 CRC cases and 515 controls from Phase 1 to find evidence of any new potential association signal. By these means, we were able to identify a region defined by rs954353, located in the 5# untranslated region of the CYR61 gene (39) . CYR61 was proposed earlier as a connection point among signaling pathways and a probable marker for early CRC detection. However, despite this interesting candidate-gene selection strategy, the rs954353 association could not be replicated in Phase 2 (933 CRC cases and 955 controls). We believe that the reduced sample size from our study may have been a key factor in its unsuccessful replication, and, therefore, larger cohorts may be needed to fully ascertain the relationship between this polymorphism and CRC genetic susceptibility.
Another candidate-gene strategy evaluated two main carcinogenesis-related pathways, Wnt and BMP and their genetic variation in EPICOLON Phase 2 (40) . A total of 45 SNPs located either exonic or regulatory regions, corresponding to 21 genes were evaluated. Unfortunately, none of the screened SNPs were significantly associated with an altered risk of CRC, considering ORs and related P values for allelic and genotypic tests (trend, dominant and recessive).
Very recently, two other candidate-gene approaches have been concluded. One of them evaluated 10 genetic variants linked to CRC risk by previous studies (historical category) and 18 selected variants from the mucin gene family in a two-stage case-control study in EPICOLON Phases 1 and 2. None of the 28 SNPs analysed in this study could be formally associated with CRC risk. However, variants in ARL11 (rs3803185), ADH1C (rs698) and GALNTL2 (rs2102302) showed some significance or were borderline significant in more than one stage (Abulí A, Fernández-Rozadilla C, Alonso-Espinaco V, Muñoz J, Gonzalo V, Bessa X, González D, Clofent J, Cubiella J, Morillas JD, Rigau J, Latorre M, Fernández-Bañares F, Peña E, Riestra S, Payá A, Jover R, Xicola RM, Llor X, Carvajal-Carmona L, Villanueva CM, Moreno V, Carracedo A, Castells A, Andreu M, Ruiz-Ponte C, Castellví-Bel S, for the Gastrointestinal Oncology Group of the Spanish Gastroenterological Association, in preparation) and may deserve to be evaluated in additional cohorts. The other recent candidate-gene strategy genotyped 172 SNPs in 84 genes located within regions 9q22-q31 and 3q21-q24, also in a two-stage case-control study in EPICOLON Phases 1 and 2. Again, none of the 172 SNPs analysed in this study could be formally associated with CRC risk. However, rs1444601 (TOPBP1) and rs13088006 (CDV3) in region 3q22 showed some significance or were borderline significant in more than one stage and may have an effect on CRC risk (Abulí A, Fernández-Rozadilla C, Giráldez MD, Muñoz J, Gonzalo V, Bessa X, Bujanda L, Reñé JM, Lanas A, García AM, Saló J, Argüello L, Vilella A, Carreño R, Jover R, Xicola RM, Llor X, Carvajal-Carmona L, Tomlinson IPM, Kerr DJ, Houlston RS, Piqué JM, Carracedo A, Castells A, Andreu M, Ruiz-Ponte C, and Castellví-Bel S, for the Gastrointestinal Oncology Group of the Spanish Gastroenterological Association, manuscript in preparation).
In addition to candidate-gene approaches, EPICOLON has also participated in external CRC GWAS by replicating their statistically significant findings in the EPICOLON cohort. In such collaborations, this consortium has contributed so far to the identification of 5 of the 16 common, low-penetrance Identification of new common low-penetrance CRC genetic variants permits to explain part of this neoplasm's heritability beyond hereditary syndromes. Therefore, it could be hypothesised that some of these variants or a combination of them may correlate with cancer phenotype. To test this possibility, the first 10 GWAS SNPs were evaluated in a genotype-phenotype correlation with several clinical and tumour-related characteristics in a two-stage case-control study in EPICOLON Phases 1 and 2 (43) . Validated results confirmed that the C allele on 8q23.3 (rs16892766) was significantly associated with advanced-stage tumours (OR, 1.48; 95% CI, 1.15-1.90; P value 5 4.9 Â 10
À3
). The G allele on 8q24.21 (rs6983267) was more common in patients with a familial history of CRC (OR, 2.02; 95% CI, 1.35-3.03; P value 5 3.9 Â 10
À4
). The combination of rs6983267 on 8q24.21 and rs9929218 on 16q22.2 was associated with a history of colorectal adenoma (carriers of GG and AA, respectively; OR, 2.28; 95% CI, 1.32-3.93; P 5 5.0 Â 10
). It was concluded that CRC susceptibility variants at 8q23.3, 8q24.21 and 16q22.2 could be associated differentially with cancer phenotype and, accordingly, these findings might be used to develop screening and surveillance strategies. Following a similar approach, the EPICOLON consortium has also been involved in the evaluation of the same 10 GWAS SNPs and its correlation with age, gender and family history in a study(Giráldez MD, Bujanda L, Abulí A, Fernández-Rozadilla C, Muñoz J, Gonzalo V, Bessa X, Jover R, Xicola RM, Llor X, Piqué JM, Carracedo A, Andreu M, Ruiz-Ponte C, Castells A, Balaguer F, Castellví-Bel, for the Gastrointestinal Oncology Group of the Spanish Gastroenterological Association, manuscript in preparation).
Future prospects
Although there has been a significant increase in the knowledge of CRC genetic susceptibility in recent years mainly due to GWAS approaches, there is still a high percentage of unidentified heritability for this cancer. From EPICOLON, we plan to continue collaborating with groups in the COGENT consortium (44) in order to identify additional CRC genetic susceptibility variants. Also, our own GWAS is in its final analysis steps and may shed new SNPs or CNVs linked to CRC genetic predisposition.
Very recently, there has been a very significant evolution regarding technology to search for genes responsible for human diseases with the advent of next-generation sequencing techniques (NGS), which have permitted to know the complete genome of several organisms (45) . These new technologies correspond to a variety of strategies based on different modifications in the DNA template preparation, sequencing process and genome imaging, as well as in alignment and assembling methods. Thus, NGS main advantage corresponds to its ability to generate a huge amount of information at a very low cost, allowing performing more than just a simple base sequence analysis. After finishing the human whole-genome NGS for some individuals, right now several massive cooperative research projects are being performed to sequence a number of individuals in order to identify structural or nucleotide variants associated to phenotypic differences (46, 47) . These personal genomics endeavours are of particular interest when they try to elucidate which genomic variation is linked to a specific disease.
The main application for NGS is human genome resequencing in order to increase our knowledge of how genetic variation affects health and disease. Also, it is feasible to direct sequencing only to genome areas of higher interest with target enrichment techniques (48) . Therefore, the more realistic NGS application nowadays corresponds to the selected sequencing of the protein coding genome or exome (whole-exome sequencing) that corresponds to 1% of all human genome (49, 50) . So far, whole-exome NGS has not been applied in CRC cases with familial aggregation with an unknown genetic cause and, accordingly, we are currently performing it in selected EPICOLON samples. 
